Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2–P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach

Publication date: December 2020Source: Journal of Molecular Graphics and Modelling, Volume 101Author(s): Ikechukwu Achilonu, Emmanuel Amarachi Iwuchukwu, Okechinyere Juliet Achilonu, Manuel Antonio Fernandes, Yasien Sayed

Source: Journal of Molecular Graphics and Modelling - September 11, 2020 Category: Molecular Biology Source Type: research